Edesa Biotech, Inc. (EDSA) - 10-Q Summary
Business Context and Reporting Period
Company: Edesa Biotech, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended December 31, 2025
Business Overview: A clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases. Key assets include EB06 (vitiligo), EB05 (ARDS), and EB01 (dermatology). The company is incorporated in British Columbia, Canada, and trades on Nasdaq.
Key Financial Metrics
| Metric | Q1 2026 (Dec 31, 2025) | Q1 2025 (Dec 31, 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,247,669) | $(1,617,253) |
| Loss Per Share (Basic/Diluted) | $(0.28) | $(0.48) |
| Operating Expenses | $2,341,383 | $1,898,689 |
| Research & Development | $1,124,727 | $1,019,818 |
| General & Administrative | $1,216,656 | $878,871 |
| Cash and Cash Equivalents (End of Period) | $12,051,748 | $1,563,502 |
| Net Cash Used in Operating Activities | $(2,087,334) | $(1,517,203) |
| Net Cash Provided by Financing Activities | $3,355,419 | $2,071,545 |
| Working Capital | $11,961,324 | Filing text does not provide a clear value |
| Accumulated Deficit | $(68,196,040) | $(60,231,745) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $0.63 million (39%) compared to the prior year quarter, driven by higher operating expenses.
- Expense Growth: Total operating expenses rose $0.44 million. R&D expenses increased $0.10 million due to preparations for the EB06 Phase 2 vitiligo study, partially offset by wind-down costs for the EB05 Phase 3 study. G&A expenses increased $0.34 million, primarily due to a significant rise in non-cash share-based compensation ($0.40 million vs. $0.08 million).
- Liquidity Improvement: Cash balances increased significantly from $1.56 million to $12.05 million, driven by financing activities including an At-The-Market (ATM) offering and prior private placements.
- Grant Income: Reimbursement grant income decreased to $0.10 million from $0.30 million in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states a material uncertainty regarding the company's ability to continue as a going concern. Continued operations depend on obtaining additional funding through financings, grants, or strategic activities.
- Capital Resources: Management expects current cash, ATM proceeds, and grant reimbursements will not be sufficient to fund operations through the end of fiscal 2026. Additional financing is required.
- Pipeline Updates:
- EB06 (Vitiligo): Received Health Canada approval for a Phase 2 study; discussions with the FDA are ongoing. Enrollment anticipated by mid-2026.
- EB05 (ARDS): Reported meeting primary and secondary endpoints in a truncated Phase 3 study in October 2025. Subgroup data is being evaluated.
- Financing Activities:
- Sold 1,177,568 common shares via the HCW ATM program for net proceeds of ~$3.4 million in Q1 2026.
- Filed a prospectus supplement on December 12, 2025, authorizing up to an additional $2.26 million under the ATM program.
- Series B-1 Preferred Shares (issued Feb 2025) and Series A-1 Preferred Shares (issued Oct 2024) remain outstanding.
- Risks: Risks include the inability to raise capital, clinical trial delays, regulatory approval uncertainties, and foreign exchange exposure (CAD/USD).
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the sufficiency of the $12.1 million cash balance to fund the planned EB06 Phase 2 study and general operations through fiscal 2026.
- EB05 Commercialization: Confirm the status of regulatory filings and commercialization plans following the positive Phase 3 results for EB05 in ARDS.
- EB06 Regulatory Status: Monitor the outcome of FDA discussions regarding the Phase 2 vitiligo study and the timeline for enrollment initiation.
- Dilution Risk: Assess the potential dilution from future equity financings required to bridge the funding gap identified by management.
- Grant Repayment Terms: Review the specific triggers for the repayment of the C$17.2 million conditionally repayable portion of the Strategic Response Fund (SRF) grant.